Literature DB >> 12774920

Immunodeficient mouse models of lymphoid tumors.

Kazunori Imada1.   

Abstract

Severe combined immunodeficient (SCID) mice lack functional T- and B-cells and readily accept human xenografts, including hematopoietic malignancies. Accordingly, SCID mice have been used to study the growth and behavior of lymphoid tumors in vivo. The SCID mouse models of disease mimic human diseases and have provided valuable information. However, this mouse strain has some residual immunity that somewhat limits posttransplantation growth of human xenografts. Recently, the SCID mutation was backcrossed onto the nonobese diabetic (NOD) strain background. The result was an animal with additional immunological defects beyond those seen in SCID mice. The NOD/SCID strain appears to be more promising as a tool for xenotransplantation of lymphoid tumors. Moreover, these SCID and NOD/SCID mouse models have been used to develop novel therapeutic strategies. Results from such studies may also help to elucidate the pathogenesis of lymphoid tumors.

Entities:  

Mesh:

Year:  2003        PMID: 12774920     DOI: 10.1007/bf02982640

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  52 in total

1.  Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.

Authors:  S Barth; M Huhn; B Matthey; R Schnell; S Tawadros; T Schinköthe; J Lorenzen; V Diehl; A Engert
Journal:  Int J Cancer       Date:  2000-06-01       Impact factor: 7.396

Review 2.  Modelling human leukemia and lymphoma in severe combined immunodeficient (SCID) mice: practical applications.

Authors:  D J Flavell
Journal:  Hematol Oncol       Date:  1996-06       Impact factor: 5.271

Review 3.  Viral pathogenesis in hu-PBL-SCID mice.

Authors:  D E Mosier
Journal:  Semin Immunol       Date:  1996-08       Impact factor: 11.130

4.  Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines.

Authors:  H J Gruss; N Boiani; D E Williams; R J Armitage; C A Smith; R G Goodwin
Journal:  Blood       Date:  1994-04-15       Impact factor: 22.113

5.  Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma.

Authors:  F Bertolini; L Fusetti; P Mancuso; A Gobbi; C Corsini; P F Ferrucci; G Martinelli; G Pruneri
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

6.  Essential role for T cells in human B-cell lymphoproliferative disease development in severe combined immunodeficient mice.

Authors:  I Johannessen; M Asghar; D H Crawford
Journal:  Br J Haematol       Date:  2000-06       Impact factor: 6.998

7.  Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.

Authors:  Chalet Tan; Thomas A Waldmann
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

8.  Engraftment of human non-Hodgkin lymphomas in mice with severe combined immunodeficiency.

Authors:  T Itoh; M Shiota; M Takanashi; I Hojo; H Satoh; A Matsuzawa; T Moriyama; T Watanabe; K Hirai; S Mori
Journal:  Cancer       Date:  1993-11-01       Impact factor: 6.860

9.  Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects.

Authors:  W A Hudson; Q Li; C Le; J H Kersey
Journal:  Leukemia       Date:  1998-12       Impact factor: 11.528

10.  The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.

Authors:  Alan F Wahl; Kerry Klussman; Jennifer D Thompson; Judy H Chen; Leigh V Francisco; Grant Risdon; Dana F Chace; Clay B Siegall; Joseph A Francisco
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

View more
  5 in total

1.  Perforin-independent rejection of transplanted human stem cells.

Authors:  S Kaiser; D Kägi; G Ihorst; U Kapp
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

Review 2.  Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.

Authors:  Christopher G England; Lixin Rui; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-14       Impact factor: 9.236

Review 3.  How animal models of leukaemias have already benefited patients.

Authors:  Julien Ablain; Rihab Nasr; Jun Zhu; Ali Bazarbachi; Valérie Lallemand-Breittenbach; Hugues de Thé
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

Review 4.  Using mouse models to study function of transcriptional factors in T cell development.

Authors:  Peng Li; Yiren Xiao; Zhixin Liu; Pentao Liu
Journal:  Cell Regen (Lond)       Date:  2012-10-10

5.  Ectopic TLX1 expression accelerates malignancies in mice deficient in DNA-PK.

Authors:  Konstantin Krutikov; Yanzhen Zheng; Alden Chesney; Xiaoyong Huang; Andrea K Vaags; Valentina Evdokimova; Margaret R Hough; Edwin Chen
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.